Mapping CD8 T Cell Epitopes in Leishmania major for Vaccine Development
Author Information
Author(s): Seyed Negar Zahedifard, Farnaz Safaiyan, Shima Gholami, Elham Doustdari, Kayhan Azadmanesh, Maryam Mirzaei, Nasir Saeedi Eslami, Sadegh Akbar Khadem, Ali Eslami far, Iraj Sharifi, Sima Rafati
Primary Institution: Pasteur Institute of Iran
Hypothesis
Can in silico predicted peptides from Leishmania major elicit a CD8 T cell response in humans?
Conclusion
The study identified specific peptides from Leishmania major that can activate CD8 T cells in HLA-A2 positive individuals, supporting the development of a peptide-based vaccine.
Supporting Evidence
- 31.6% of HLA-A2+ recovered individuals responded to peptide pool II.
- 13.3% of HLA-A2+ recovered individuals responded to peptide pool IV.
- Responses were significantly higher in HLA-A2+ individuals compared to HLA-A2− individuals.
Takeaway
Researchers found that certain pieces of the Leishmania parasite can help the immune system fight the disease by activating special cells called CD8 T cells.
Methodology
The study used in silico tools to predict CD8 T cell epitopes from six Leishmania major proteins and evaluated their immunogenicity through in vitro assays with PBMCs from recovered individuals.
Potential Biases
Potential bias in participant selection and the reliance on in vitro methods for assessing immune responses.
Limitations
The study's findings are based on a limited sample size and may not be generalizable to all populations.
Participant Demographics
67 individuals (28 men and 39 women) aged 8 to 78 years, all recovered from cutaneous leishmaniasis.
Statistical Information
P-Value
0.03
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website